P&F Products & Features GmbH Announces Acquisition of AVVie GmbH

P&F Products & Features GmbH (P&F) has announced the acquisition of AVVie GmbH, a strategic move aimed at enhancing its structural heart portfolio through the integration of the AngelValve™ Augmentation System. The transaction, which was disclosed on August 5, 2026, involves an undisclosed amount and underscores P&F's commitment to advancing innovative therapies in the medical technology sector, particularly for mitral regurgitation.

AVVie GmbH, founded by renowned cardiac surgeon Prof. Werner Mohl, has developed the AngelValve™, a novel transcatheter solution designed to address significant unmet needs in the treatment of mitral valve disease. Mitral regurgitation affects more than 13 million individuals across Europe and the United States, yet only a small fraction—approximately 5%—of those with moderate to severe cases currently receive treatment. This acquisition positions P&F to play a pivotal role in closing this treatment gap, thereby improving the quality of life for millions of patients.

The strategic rationale behind this acquisition lies in the complementary strengths of both companies. AVVie’s research and development infrastructure, along with its intellectual property, will be combined with P&F's extensive capabilities in product development, clinical and regulatory affairs, and commercialization. This synergy is expected to accelerate innovation and shorten development timelines for the AngelValve™ platform, allowing P&F to enhance its offerings in the rapidly evolving structural heart therapy market.

The medical technology sector, particularly in the field of cardiovascular solutions, is experiencing significant growth driven by an aging population and increasing prevalence of heart diseases. P&F's acquisition of AVVie aligns with broader industry trends that emphasize the need for innovative and effective treatment options. By integrating AVVie’s cutting-edge technology, P&F is well-positioned to strengthen its market presence and contribute to advancements in structural heart therapies.

In conclusion, the acquisition of AVVie GmbH marks a significant step for P&F Products & Features as it seeks to solidify its leadership in the structural heart therapy market. This strategic move not only enhances P&F's product offerings but also reflects a broader commitment to addressing critical healthcare challenges associated with mitral regurgitation. As the industry continues to evolve, the combined expertise of P&F and AVVie has the potential to deliver meaningful innovations that benefit both healthcare providers and patients worldwide.